{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:38:37Z","timestamp":1791218317735,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains to be determined if vaccine immunogenicity is comparable in all previously infected subjects. This study presents detailed immunological evidence to clarify the requirements for one- or two-dose primary vaccination series for naturally primed individuals. The main objective was to evaluate the immune response to COVID-19 mRNA vaccination to establish the most appropriate vaccination regimen to induce robust immune responses in individuals with prior SARS-CoV-2 infection. The main outcome measure was a functional immunity score (zero to three) before and after vaccination, based on anti-RBD IgG levels, serum capacity to neutralize live virus and IFN-\u03b3 secretion capacity in response to SARS-CoV-2 peptide pools. One point was attributed for each of these three functional assays with response above the positivity threshold. The immunity score was compared based on subjects\u2019 symptoms at diagnosis and\/or serostatus prior to vaccination. None of the na\u00efve participants (n=14) showed a maximal immunity score of three following one dose of vaccine compared to 84% of the previously infected participants (n=55). All recovered individuals who did not have an immunity score of three were seronegative prior to vaccination, and 67% had not reported symptoms resulting from their initial infection. Following one dose of vaccine, their immune responses were comparable to na\u00efve individuals, with significantly weaker responses than individuals who were symptomatic during infection. These results indicate that the absence of symptoms during initial infection and negative serostatus prior to vaccination predict the strength of immune responses to COVID-19 mRNA vaccine. Altogether, these findings highlight the importance of administering the complete two-dose primary regimen and following boosters of mRNA vaccines to individuals who experienced asymptomatic SARS-CoV-2 infection.<\/jats:p>","DOI":"10.3389\/fimmu.2022.930252","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T02:19:15Z","timestamp":1665713955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine"],"prefix":"10.3389","volume":"13","author":[{"given":"Sabryna","family":"Nantel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eete","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Carbonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henintsoa","family":"Rabezanahary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-\u00c8ve","family":"Hamelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Savard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Longtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"De Serres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Corbeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Gilca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Decaluwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"New Engl J Med"},{"key":"B3","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"The Lancet Infectious diseases"},{"key":"B4","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B5","article-title":"Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the united states","year":"2022"},{"key":"B6","article-title":"NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2","year":"2022"},{"key":"B7","article-title":"COVID-19 treatment guidelines \u2013 prevention of SARS-CoV-2 infection, prevention of SARS-CoV-2 infection","year":"2022"},{"key":"B8","article-title":"Canadian Immunization guide \u2013 COVID-19 vaccin","year":"2022"},{"key":"B9","article-title":"Overview of the implementation of COVID-19 vaccination strategies and deployment plans in the EU\/EEA","year":"2022"},{"key":"B10","article-title":"Persistent cellular immunity to SARS-CoV-2 infection","author":"Breton","year":"2020","journal-title":"bioRxiv preprint Server Biol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2021.04.19.21255739","DOI":"10.1101\/2021.04.19.21255739","article-title":"Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory b and T cells","author":"Cohen","year":"2021","journal-title":"medRxiv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat Microbiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI149154","article-title":"One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19","volume":"131","author":"Levi","year":"2021","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e149150","DOI":"10.1172\/JCI149150","article-title":"First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19","volume":"131","author":"Mazzoni","year":"2021","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2021.02.05.21251182","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory b cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"109570","DOI":"10.1016\/j.celrep.2021.109570","article-title":"Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals","volume":"36","author":"Lozano-Ojalvo","year":"2021","journal-title":"Cell Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12997","article-title":"The REinfection in COVID-19 estimation of risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers","volume":"16","author":"Racine","year":"","journal-title":"Influenza Other Respir Viruses"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.100","article-title":"SARS-CoV-2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup","volume":"57","author":"Stadlbauer","year":"2020","journal-title":"Curr Protoc Microbiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3138\/jammi-2021-0026","article-title":"Evaluation of the performance of multiple immunoassay diagnostic platforms on the national microbiology laboratory SARS-CoV-2 national serology panel","author":"Dibernardo","year":"2022","journal-title":"Off J Assoc Med Microbiol Infect Dis Canada Preprint"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00280-15","article-title":"A single dose of an avian H3N8 influenza virus vaccine is highly immunogenic and efficacious against a recently emerged seal influenza virus in mice and ferrets","volume":"89","author":"Baz","year":"2015","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"1938","author":"Reed","year":"","journal-title":"Am J Hyg"},{"key":"B29","doi-asserted-by":"publisher","first-page":"51643","DOI":"10.3791\/51643","article-title":"Development of an IFN-\u03b3 ELISpot assay to assess varicella-zoster virus-specific cell-mediated immunity following umbilical cord blood transplantation","author":"Salem Fourati","year":"2014","journal-title":"J Visualized Experiments JoVE"},{"key":"B30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2","volume":"27","author":"Grifoni","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.chom.2021.06.001","article-title":"A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits fc-mediated antibody effector functions and T cell responses","volume":"29","author":"Tauzin","year":"2021","journal-title":"Cell Host Microbe"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2","volume":"325","author":"Saadat","year":"2021","journal-title":"Jama"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"New Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet (London England)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0470","article-title":"Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants","volume":"327","author":"Accorsi","year":"2022","journal-title":"Jama"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.15585\/mmwr.mm7104e2","article-title":"COVID-19 incidence and death rates among unvaccinated and fully vaccinated adults with and without booster doses during periods of delta and omicron variant emergence - 25 U.S. jurisdictions, April 4-December 25, 2021","volume":"71","author":"Johnson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2022.02.06.22270558","DOI":"10.1101\/2022.02.06.22270558","article-title":"Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the united states: A prospective observational study","volume":"7","author":"Lauring","year":"2022","journal-title":"medRxiv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104e3","article-title":"Effectiveness of a third dose of mRNA vaccines against COVID-19-Associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 states, august 2021-January 2022","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.4.2200077","article-title":"Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA.1 variant compared with the delta variant, Norway, December 2021 to January 2022","volume":"27","author":"Veneti","year":"2022","journal-title":"Euro Surveill"},{"key":"B42","doi-asserted-by":"publisher","first-page":"12.30.21268565","DOI":"10.1101\/2021.12.30.21268565","article-title":"Effectiveness of COVID-19 vaccines against omicron or delta symptomatic infection and severe outcomes","author":"Buchan","year":"2022","journal-title":"medRxiv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"12.07.21267432","DOI":"10.1101\/2021.12.07.21267432","article-title":"Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies","author":"Wilhelm","year":"2021","journal-title":"medRxiv"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","volume":"28","author":"Wratil","year":"2022","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS CoV-2 omicron-reactive T- and b cell responses in COVID-19 vaccine recipients","volume":"2022","author":"GeurtsvanKessel","year":"","journal-title":"Sci Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.20.21268130","article-title":"High rate of asymptomatic carriage associated with variant strain omicron","author":"Garrett","year":"2022","journal-title":"medRxiv"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"Payne","year":"2021","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 vaccines","volume":"325","author":"Creech","year":"2021","journal-title":"Jama"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death & Differentiation"},{"key":"B51","unstructured":"OrganizationWH\n          Tracking SARS-CoV-2 variants2021"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.930252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T02:19:23Z","timestamp":1665713963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.930252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2022.930252"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.930252","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.29.22272714","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"930252"}}